Bioyond Technology, a Chinese provider of intelligent automation software for life sciences, medical and health care companies, said it has received about $29 million in Series A and A+ funding rounds. The A+ round was led by Boyuan Capital and Lilly Asia Fund with additional participation from CICC Qide Fund, Qiming Venture Capital, Sequoia China Seed Fund and Zhangke Harun Fund.
Bioyond is headquartered in Shanghai Zhangjiang Science City and provides automation solutions for firms engaged in the small molecule drugs, biologics, cellular gene therapy, Chinese medicine, synthetic biology, histology research, clinical diagnostics and materials science industries.
According to a statement, the company will use the capital infusion for product development and production, platform construction, and market expansion to accelerate the provision of easier-to-use and more efficient automation products and solutions for pharmaceuticals, clinical diagnostics, scientific research, and material chemicals. Bioyond Technology was founded in 2021.